Division of Vascular and Interventional Radiology, Department of Medical Imaging, Joint Department of Medical Imaging, 7938University of Toronto, Toronto, ON, Canada.
Division of Vascular and Interventional Radiology, Department of Medical Imaging, The Ottawa Hospital, 6363University of Ottawa, Ottawa, ON, Canada.
Vasc Endovascular Surg. 2022 May;56(4):357-368. doi: 10.1177/15385744211068648. Epub 2022 Feb 11.
Endovascular therapy in the management of de novo common femoral disease remains controversial. Considerable interest has been generated in recent years due to recent technological advancement in the design of vascular stents. In particular, SUPERA (Abbot Vascular Inc, Santa Clara USA) stents are designed to offer increased flexibility and less adverse interactions with the arterial wall, thus making it potentially better suited for common femoral lesions. However, despite such theoretical advantages, there is lack of data in its use in clinical practice. This study provides illustrative examples of SUPERA stents in different clinical settings and contributes to important clinical data for the overall efficacy and safety profile of endovascular interventions in common femoral artery (CFA) disease.
Retrospective analysis of all endovascular CFA procedures between January 1, 2011, and December 31, 2019, was conducted. Data collected included demographics, clinical symptoms, medical comorbidities, procedural characteristics, and immediate and short-term complications. Detailed analysis was performed on the stenting cohort.
During our study period, a total of 69 patients underwent endovascular interventions involving the CFA at our institution, of which 16 patients had stenting procedures for a total of 18 stent deployments. Technical success was achieved in all stenting procedures. A total of 15 SUPERA stents were placed in 13 patients. No stent fractures were observed. Overall primary patency rate of SUPERA stents at the time of 12-month follow-up was 100% in patients who had a follow-up assessment (n = 12 stents).
Endovascular intervention of the CFA is an evolving topic in the interventional radiology and vascular surgery community. Recent development of newer generation of devices such as SUPERA peripheral stents offers significant potential benefits given their inherent design. Despite the theoretically promising design of the SUPERA, there is a lack of data to support its use. This study contributes important patient-level data for SUPERA stent deployments.
在新出现的股总动脉疾病的治疗中，血管内治疗仍然存在争议。近年来，血管支架设计方面的技术进步引起了广泛关注。特别是，SUPERA（美国雅培血管公司）支架的设计旨在提供更大的灵活性，并减少与动脉壁的不良相互作用，从而使其更适合股总动脉病变。然而，尽管有这样的理论优势，但在临床实践中使用该支架的数据仍然缺乏。本研究提供了 SUPERA 支架在不同临床环境下的实例，为股总动脉（CFA）疾病的血管内干预的整体疗效和安全性提供了重要的临床数据。
对 2011 年 1 月 1 日至 2019 年 12 月 31 日期间所有 CFA 血管内治疗的病例进行回顾性分析。收集的数据包括人口统计学资料、临床症状、合并症、手术特征以及即时和短期并发症。对支架置入组进行了详细分析。
在我们的研究期间，共有 69 例患者在我院接受了 CFA 的血管内治疗，其中 16 例患者进行了支架置入术，共进行了 18 次支架置入。所有支架置入术均获得技术成功。共 13 例患者中放置了 15 个 SUPERA 支架。未观察到支架断裂。在 12 个月随访时，有 12 个支架进行了随访评估，所有患者的 SUPERA 支架的初始通畅率为 100%。
CFA 的血管内干预是介入放射学和血管外科学领域的一个不断发展的课题。新一代设备（如 SUPERA 外周支架）的发展具有显著的潜在优势，因为它们具有内在的设计。尽管 SUPERA 的设计理论上很有前景，但缺乏支持其使用的数据。本研究为 SUPERA 支架置入提供了重要的患者水平数据。
